Skip to main content
Top
Published in: Infection 5/2017

Open Access 01-10-2017 | Original Paper

Assessing the risk and disease burden of Clostridium difficile infection among patients with hospital-acquired pneumonia at a University Hospital in Central China

Authors: Chunhui Li, Juping Duan, Sidi Liu, Xiujuan Meng, Chenchao Fu, Cui Zeng, Anhua Wu

Published in: Infection | Issue 5/2017

Login to get access

Abstract

Purpose

Hospital-acquired pneumonia (HAP) remains one of the major hospital-acquired infections in China. Antibiotic treatment of HAP may lead to subsequent Clostridium difficile infection (CDI). Baseline data on the occurrence of CDI among HAP patients in China are currently unavailable. This study examines the risk and disease burden of CDI among HAP hospitalized patients (HAP-CDI).

Methods

We conducted a prospective study among ICU patients with HAP and hospital-onset diarrhea from January 2014 to December 2014 in a teaching hospital in China. All stool specimens were cultured for C. difficile which were typed by MLST. We used univariate and multivariable regression analyses to identify risk factors of HAP-CDI.

Findings

In total, 369 patients who met the inclusion criteria were enrolled. Thirty-two patients tested C. difficile positive. Among the isolated C. difficile strains, 90.63% (29/32) isolates were toxinogenic. Various MLST types were identified. The incidence of HAP-CDI was 11.67/10,000 patient days (95% CI, 7.97–16.55). Nineteen patients died from complications. The attributable mortality rate was 5.15% (19/369). The mortality rate of HAP-CDI group was 13.79% which was higher than HAP-non-CDI group. Univariate analyses demonstrated that old age, receiving antibiotics (OR = 8.70) and glucocorticoids (OR = 7.71) 1 month prior to hospitalization, respiratory failure (OR = 3.28) and receiving antimicrobials during hospitalization (OR = 1.15) were the risk factors associated with CDI. Multivariate conditional logistic regression analysis demonstrated the similar results.

Conclusion

CDI was common among patients discharged from hospital for HAP at a university hospital. Prevention of the spreading of C. difficile among hospitalized patients is urgently needed.
Appendix
Available only for authorised users
Literature
4.
go back to reference Miller BA, Chen LF, Sexton DJ, Anderson DJ. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol. 2011;32:387–90. doi:10.1086/659156.CrossRefPubMed Miller BA, Chen LF, Sexton DJ, Anderson DJ. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol. 2011;32:387–90. doi:10.​1086/​659156.CrossRefPubMed
5.
go back to reference Frédéric Barbut OC, Kuijper J, Nagy E, Rupnik M, Tvede M, Wilcox M. Clostridium difficile infection in Europe, A CDI Europe report. 2013. Frédéric Barbut OC, Kuijper J, Nagy E, Rupnik M, Tvede M, Wilcox M. Clostridium difficile infection in Europe, A CDI Europe report. 2013.
6.
go back to reference Li C, Wen X, Ren N, Zhou P, Huang X, Gong R, et al. Point-prevalence of healthcare-associated infection in china in 2010: a large multicenter epidemiological survey. Infect Control Hosp Epidemiol. 2014;35:1436–7. doi:10.1086/678433.CrossRefPubMed Li C, Wen X, Ren N, Zhou P, Huang X, Gong R, et al. Point-prevalence of healthcare-associated infection in china in 2010: a large multicenter epidemiological survey. Infect Control Hosp Epidemiol. 2014;35:1436–7. doi:10.​1086/​678433.CrossRefPubMed
8.
11.
go back to reference Owens RC Jr, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008;46:S19–31. doi:10.1086/521859.CrossRefPubMed Owens RC Jr, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008;46:S19–31. doi:10.​1086/​521859.CrossRefPubMed
12.
go back to reference Drudy D, Harnedy N, Fanning S, Hannan M, Kyne L. Emergence and control of fluoroquinolone-resistant, toxin a-negative, toxin B-Positive Clostridium difficile. Infect Cont Hosp Epidemiol. 2007;28:932–40. doi:10.1086/519181.CrossRef Drudy D, Harnedy N, Fanning S, Hannan M, Kyne L. Emergence and control of fluoroquinolone-resistant, toxin a-negative, toxin B-Positive Clostridium difficile. Infect Cont Hosp Epidemiol. 2007;28:932–40. doi:10.​1086/​519181.CrossRef
14.
go back to reference Niederman MS. Hospital-acquired pneumonia, health care-associated pneumonia, ventilator-associated pneumonia, and ventilator-associated tracheobronchitis: definitions and challenges in trial design. Clin Infect Dis. 2010;51:S12–7. doi:10.1086/653035.CrossRefPubMed Niederman MS. Hospital-acquired pneumonia, health care-associated pneumonia, ventilator-associated pneumonia, and ventilator-associated tracheobronchitis: definitions and challenges in trial design. Clin Infect Dis. 2010;51:S12–7. doi:10.​1086/​653035.CrossRefPubMed
15.
go back to reference McDonald LC, Coignard B, Dubberke E, Song X, Horan T, Kutty PK, et al. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol. 2007;28:140–5. doi:10.1086/511798.CrossRefPubMed McDonald LC, Coignard B, Dubberke E, Song X, Horan T, Kutty PK, et al. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol. 2007;28:140–5. doi:10.​1086/​511798.CrossRefPubMed
16.
go back to reference Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431–55. doi:10.1086/651706.CrossRefPubMed Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431–55. doi:10.​1086/​651706.CrossRefPubMed
18.
go back to reference Kato H, Kato N, Watanabe K, Iwai N, Nakamura H, Yamamoto T, et al. Identification of toxin A-negative, toxin B-positive Clostridium difficile by PCR. J Clin Microbiol. 1998;36:2178–82.PubMedPubMedCentral Kato H, Kato N, Watanabe K, Iwai N, Nakamura H, Yamamoto T, et al. Identification of toxin A-negative, toxin B-positive Clostridium difficile by PCR. J Clin Microbiol. 1998;36:2178–82.PubMedPubMedCentral
19.
go back to reference Pituch H, Kreft D, Obuch-Woszczatynski P, Wultanska D, Meisel-Mikolajczyk F, Luczak M, et al. Clonal spread of a Clostridium difficile strain with a complete set of toxin A, toxin B, and binary toxin genes among Polish patients with Clostridium difficile-associated diarrhea. J Clin Microbiol. 2005;43:472–5. doi:10.1128/JCM.43.1.472-475.2005.CrossRefPubMedPubMedCentral Pituch H, Kreft D, Obuch-Woszczatynski P, Wultanska D, Meisel-Mikolajczyk F, Luczak M, et al. Clonal spread of a Clostridium difficile strain with a complete set of toxin A, toxin B, and binary toxin genes among Polish patients with Clostridium difficile-associated diarrhea. J Clin Microbiol. 2005;43:472–5. doi:10.​1128/​JCM.​43.​1.​472-475.​2005.CrossRefPubMedPubMedCentral
21.
go back to reference Rotstein C, Evans G, Born A, Grossman R, Light RB, Magder S, et al. Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults. Can J Infect Dis Med Microbiol. 2008;19:19–53.PubMedPubMedCentral Rotstein C, Evans G, Born A, Grossman R, Light RB, Magder S, et al. Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults. Can J Infect Dis Med Microbiol. 2008;19:19–53.PubMedPubMedCentral
25.
go back to reference Chen Y, Glass K, Liu B, Korda RJ, Riley TV, Kirk MD. Burden of Clostridium difficile infection: associated hospitalization in a cohort of middle-aged and older adults. Am J Infect Control. 2017;. doi:10.1016/j.ajic.2016.12.006. Chen Y, Glass K, Liu B, Korda RJ, Riley TV, Kirk MD. Burden of Clostridium difficile infection: associated hospitalization in a cohort of middle-aged and older adults. Am J Infect Control. 2017;. doi:10.​1016/​j.​ajic.​2016.​12.​006.
29.
go back to reference Winslow BT, Onysko M, Thompson KA, Caldwell K, Ehlers GH. Common questions about Clostridium difficile infection. Am Fam Physician. 2014;89:437–42.PubMed Winslow BT, Onysko M, Thompson KA, Caldwell K, Ehlers GH. Common questions about Clostridium difficile infection. Am Fam Physician. 2014;89:437–42.PubMed
31.
go back to reference Shen EP, Surawicz CM. Current treatment options for severe Clostridium difficile-associated disease. Gastroenterol Hepatol (NY). 2008;4:134–9. Shen EP, Surawicz CM. Current treatment options for severe Clostridium difficile-associated disease. Gastroenterol Hepatol (NY). 2008;4:134–9.
Metadata
Title
Assessing the risk and disease burden of Clostridium difficile infection among patients with hospital-acquired pneumonia at a University Hospital in Central China
Authors
Chunhui Li
Juping Duan
Sidi Liu
Xiujuan Meng
Chenchao Fu
Cui Zeng
Anhua Wu
Publication date
01-10-2017
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 5/2017
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-017-1024-1

Other articles of this Issue 5/2017

Infection 5/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.